Objective:To investigate the clinical efficacy of different doses of pregabalin in the treatment of acute pain in elderly patients with herpes zoster(HZ).Methods:Elderly patients with acute pain due to HZ(n=90)treated in Yichang Central People's Hospital from January 2021 to December 2022 were randomly divided into three groups according to the dose of pregabalin:150 mg/d as the low-dose group(n=30),300 mg/d as the medium-dose group(n=30),and 600 mg/d as the high-dose group(n=30).The visual analog scale(VAS),dermatology life quality index(DLQI),and occurrence of complications were evaluated at 1,2,4,and 8 weeks after treatment.Results:Compared within the groups,the VAS and DLQI scores of the three groups showed a significant downward trend at 1,2,4,and 8 weeks after treatment(all P＜0.05),but there was no significant difference among the groups(all P＞0.05).The number of patients with dizziness in the medium-dose and high-dose groups was significantly higher than that in the low-dose group,and the number of patients with somnolence in the high-dose group was significantly higher than that in the low-dose group(all P＜0.05).There was no significant difference in the occurrence of postherpetic neuralgia and ataxia among the three groups(all P＞0.05).Conclusion:Low-dose pregabalin has good efficacy and fewer adverse reactions in the treatment of acute pain in elderly patients with HZ,and it is worthy of clinical recommendation.
维普
万方数据
